Aenova Group merges with Haupt Pharma; FDA cites Smruthi India plant; Ranbaxy making malaria drug;

@EricPFierce: Is there a connection between pharma DTC spending and job cuts? In some cases, yes. FiercePharma special report | Follow @EricPFierce

> Contract manufacturer Aenova Group say it is merging with Haupt Pharma, a German pharmaceutical company specializing in contract development and manufacturing. Release

> Indian drugmaker Smruthi Organics announced that the FDA has found issues with its plant in Solapur. Story

> Generic drugmaker Heritage Pharmaceuticals says it now has a generic of antibiotic Achromycin V available, pointing out that tetracycline HCl capsules have been on the FDA shortage list for two years. Release

> Albemarle says it expects production at a new kilo lab at its active pharmaceutical ingredient (API) plant in South Haven, MI, to begin in January. Release

And Finally... Ranbaxy Laboratories has gotten approval in India to sell the malaria drug Synriam. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.